Heart Failure - Bayer supports education for clinicians on heart failure with mildly reduced or preserved ejection fraction to address disease burden, care gaps, and evidence for recommended therapies.
Funder: Bayer
Due Dates: Monthly review (complete proposals)
Funding Amounts: Not specified
Summary: Supports medical education on HFmrEF and HFpEF, emphasizing disease burden, care gaps, and evidence for non-steroidal mineralocorticoid receptor antagonists.
Key Information: Providers must supply their most recent accreditation letter and status, and proposals must meet commercial-support standards.
Bayer’s Heart Failure medical educational grant program supports education on heart failure with mildly reduced or preserved ejection fraction (HFmrEF and HFpEF), focusing on patients with left ventricular ejection fraction of at least 40%. Intended audiences include primary care clinicians, nurses, physician assistants, cardiologists, endocrinologists, nephrologists, and internal medicine clinicians. Educational priorities include contemporary disease definitions, epidemiology, clinical outcomes, pathophysiology, and the importance of coexisting conditions.
The program also addresses current standards of care, treatment gaps, real-world use of recommended therapies, and residual risk. It emphasizes the unique properties of non-steroidal mineralocorticoid receptor antagonists compared with steroidal agents, along with efficacy evidence, safety, and tolerability. Named evidence priorities are FINEARTS-HF and relevant subanalyses, as well as FINEHEART.